Dr. Bertozzi is a world-renowned Nobel Laureate, scientist, academician, and pioneer in chemical biology who provides valuable leadership to the board's oversight of Lilly's discovery and development programs. Dr. Bertozzi has decades of groundbreaking research experience, offering a valuable perspective and resource to the board and management in pharmaceutical research and discovery across multiple therapeutic areas. Through her work founding and advising various biotechnology companies, Dr. Bertozzi has a deep understanding of the challenges, perspectives, and opportunities for translating basic scientific research into therapeutic application. Dr. Bertozzi also brings commercialization experience to the board through her work founding biotechnology companies and leadership roles in more than a dozen academic and scientific advisory boards and life sciences companies, bridging academic discovery and pharmaceutical innovation. Age: 59 Director Since: 2025 Board Committees: Ethics and Compliance Science and Technology Other Public Boards: OmniAb, Inc. Recent Prior Public Boards: Alnylam Pharmaceuticals, Inc. Key Skills: CAREER HIGHLIGHTS Stanford University Anne T. and Robert M. Bass Professor of Chemistry, Professor of Chemical and Systems Biology and Radiology by courtesy (2015 - present) Baker Family Director of Sarafan ChEM-H (2017 - present) Howard Hughes Medical Institute Investigator (2000 - present) OTHER HIGHLIGHTS Recipient of numerous prizes and honors, including: Nobel Prize in Chemistry Lemelson-MIT award for inventors Whistler Award Ernst Schering Prize MacArthur Foundation Fellowship Member, National Academy of Medicine; National Academy of Sciences; American Academy of Arts and Sciences; and German Academy of Sciences Leopoldina